BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25166873)

  • 1. Biomarker testing in non-small cell lung cancer: a clinician's perspective.
    Bernicker E
    Arch Pathol Lab Med; 2015 Apr; 139(4):448-50. PubMed ID: 25166873
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular prognostication of non-small cell lung cancer.
    Tsao MS; Jablons DM
    Semin Thorac Cardiovasc Surg; 2013; 25(1):4-7. PubMed ID: 23800523
    [No Abstract]   [Full Text] [Related]  

  • 3. [Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 3. Chemotherapy for patients with non-small cell lung cancer, 2) Driver mutation and molecular-targeted therapy in lung cancer].
    Maemondo M
    Nihon Naika Gakkai Zasshi; 2014 Jun; 103(6):1314-21. PubMed ID: 25151796
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular targeted therapy in lung cancer.
    Fujioka N; Bitterman PB
    Minn Med; 2012 Oct; 95(10):38-41. PubMed ID: 23193704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
    Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers in lung adenocarcinoma: a decade of progress.
    Sholl LM
    Arch Pathol Lab Med; 2015 Apr; 139(4):469-80. PubMed ID: 25255293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line therapy of mutated non-small cell lung cancer: an update.
    Stöhlmacher-Williams J
    Onkologie; 2012; 35(5):293-9. PubMed ID: 22868512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung cancer in the era of targeted therapy: a cytologist's perspective.
    Zakowski MF
    Arch Pathol Lab Med; 2013 Dec; 137(12):1816-21. PubMed ID: 23597048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.
    Cagle PT; Sholl LM; Lindeman NI; Alsabeh R; Divaris DX; Foulis P; Lee G; Neal JW; Nowak JA; Yu PP;
    Arch Pathol Lab Med; 2014 Feb; 138(2):171-4. PubMed ID: 23808401
    [No Abstract]   [Full Text] [Related]  

  • 10. The tissue is the issue: personalized medicine for non-small cell lung cancer.
    Hirsch FR; Wynes MW; Gandara DR; Bunn PA
    Clin Cancer Res; 2010 Oct; 16(20):4909-11. PubMed ID: 20926402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Personalizing" therapy for non-small cell lung cancer.
    D'Cunha J
    Semin Thorac Cardiovasc Surg; 2010; 22(2):118-20. PubMed ID: 21092888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted treatment tested as potential cancer cure.
    Hayden EC
    Nature; 2011 Nov; 479(7373):281. PubMed ID: 22094668
    [No Abstract]   [Full Text] [Related]  

  • 13. Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.
    Planchard D; Remon J; Nowak F; Soria JC
    Am Soc Clin Oncol Educ Book; 2017; 37():12-17. PubMed ID: 28561640
    [No Abstract]   [Full Text] [Related]  

  • 14. Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?
    Booton R; Blackhall F; Kerr K
    Thorax; 2011 Apr; 66(4):273-5. PubMed ID: 21345972
    [No Abstract]   [Full Text] [Related]  

  • 15. The future of oncology treatment through diagnostic testing.
    Oakley G
    MLO Med Lab Obs; 2013 Dec; 45(12):38. PubMed ID: 24409595
    [No Abstract]   [Full Text] [Related]  

  • 16. Tissue sampling in lung cancer: a review in light of the MERIT experience.
    Reck M; Hermes A; Tan EH; Felip E; Klughammer B; Baselga J
    Lung Cancer; 2011 Oct; 74(1):1-6. PubMed ID: 21658788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.
    Adamson RT
    Am J Manag Care; 2013 Dec; 19(19 Suppl):s398-404. PubMed ID: 24494721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.
    VanderLaan PA; Chen Y; DiStasio M; Rangachari D; Costa DB; Heher YK
    Clin Lung Cancer; 2018 Sep; 19(5):e589-e590. PubMed ID: 29798809
    [No Abstract]   [Full Text] [Related]  

  • 19. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
    Buikhuisen WA; Burgers JA; Vincent AD; Schellens JH; Beijnen JH; Smit EF; Joerger M
    J Clin Oncol; 2010 Sep; 28(27):e482-3; author reply e484. PubMed ID: 20606096
    [No Abstract]   [Full Text] [Related]  

  • 20. [Lung cancer: progress in diagnosis and treatments. Topics: IV. Recent topics; 1. Driver mutations in non-small cell lung cancer].
    Mano H
    Nihon Naika Gakkai Zasshi; 2014 Jun; 103(6):1355-9. PubMed ID: 25151801
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.